Abstract
Purpose: Malignant extrinsic ureteral obstruction (MEUO) is a challenging clinical problem. Many factors weigh into the decision to proceed with retrograde ureteral stent (RUS), nephrostomy tube (NT), or observation; however, there is no consensus for the optimal approach. The objective of this study was twofold. First, to determine practice patterns by correlating patient, hospital, and disease characteristics to manage MEUO; second, to describe treatment trends of MEUO over time. Materials and Methods: Using the National Inpatient Sample 2010-2015, we abstracted all adults with diagnoses of hydronephrosis and concurrent metastasis or lymphoma, excluding any record with a diagnosis of urinary tract stone. Multinomial regression assessed predictors of undergoing no decompression, stenting, or nephrostomy. Quarterly trends and annual percentage change of MEUO prevalence and percentage decompressed with stent vs nephrostomy were calculated. Results: There were an estimated 238,500 cases of MEUO from 2010 to 2015, of which 18.0% underwent decompression with RUS and 11.4% NT. On multinomial regression, prostate (odds ratio [OR] 1.5), bladder (1.6), cervical (1.6) cancer, academic hospitals (1.4), and acute kidney injury were among factors that most significantly increased odds of undergoing NT. Factors that significantly increased odds of undergoing RUS included colon (OR 1.4), rectal/anal (1.3), ovarian (1.2) cancer, Midwest (vs northeast) hospitals (1.4), and female gender (1.4), whereas decreased odds of RUS were associated with bladder cancer (0.7), nonwhite race (0.8), and weekend admission (0.8). While MEUO prevalence has been increasing on an average of 2.9%/year, decompression rates have been decreasing, driven solely by a decrease in RUS of 3.8%/year on average. Conclusions: There is substantial variation in approach for MEUO among patient, hospital, and disease types, with an overall decline in stenting compared with steady nephrostomy use. Further investigation into best approaches for certain patient characteristics and disease types is needed to standardize care and reduce disparities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.